Skip to main content

Table 2 Univariate Cox model for exploring the association between FT and clinical outcomes in PD before and after weighting

From: Facial tremor in patients with Parkinson’s disease: prevalence, determinants and impacts on disease progression

  Unweighted sample Weighted sample
HR (95%CI) P-value HR (95%CI) P-value
Presence of FT at baseline
 Time to death 0.41 (0.22–0.80) 0.006* 0.62 (0.31–1.22) 0.166
 Time to UPDRS-III 11-point increase 0.77 (0.43–1.30) 0.339 0.98 (0.54–1.76) 0.934
 Time to conversion to H&Y stage ≥3 0.98 (0.50–1.78) 0.938 0.66 (0.33–1.30) 0.224
 Time to dyskinesia 0.41 (0.14–0.95) 0.061 0.44 (0.17–1.17) 0.101
 Time to MoCA 3-point decrease 0.93 (0.51–1.61) 0.793 0.67 (0.36–1.23) 0.198
FT as initial symptom
 Time to death 2.82 (1.55–5.11) < 0.001* 1.75 (0.55–5.54) 0.342
 Time to UPDRS-III 11-point increase 0.97 (0.60–1.55) 0.889 0.74 (0.24–2.31) 0.606
 Time to conversion to H&Y stage ≥3 1.24 (0.69–2.12) 0.467 0.34 (0.08–1.56) 0.167
 Time to dyskinesia 0.51 (0.21–1.27) 0.149 0.81 (0.18–3.70) 0.790
 Time to MoCA 3-point decrease 1.04 (0.63–1.72) 0.885 0.45 (0.13–1.63) 0.226
  1. FT Facial tremor, PD Parkinson’s disease, UPDRS Unified PD Rating Scale, MoCA Montreal Cognitive Assessment
  2. * Significant difference